<DOC>
	<DOCNO>NCT00228553</DOCNO>
	<brief_summary>A 12 Month , Open-Label , Flexible Dosage Extension Study Safety Efficacy Armodafinil ( CEP-10953 ) Treatment Patients Excessive Sleepiness Associated Narcolepsy , Obstructive Sleep Apnea/Hypopnea Syndrome , Chronic Shift Work Sleep Disorder</brief_summary>
	<brief_title>Extension Study Safety Efficacy Armodafinil Treatment Patients With Excessive Sleepiness</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Sleep Disorders , Circadian Rhythm</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<criteria>Patients include study follow criterion meet : Men woman ( outpatient ) ethnic origin , 18 65 year age ( inclusive ) begin respective doubleblind study , eligible . The patient complete cephalonsponsored doubleblind study ( study C10953/3020/NA/MN , C10953/3021/AP/MN , C10953/3022/CM/MN , C10953/3025/AP/MN ) , investigator recommend enrolled . Patients OSAHS must continue regular user nCPAP therapy , investigator considers remain effective . Patients chronic SWSD must work 5 nights/month , night shift include least 6 hour 2200 0800 long 12 hour duration . The patient consider good health . Women must surgically sterile , 2 year postmenopausal , childbearing potential , must use medically accept method birth control ( ie , barrier method spermicide , steroidal contraceptive [ oral , implanted , DepoProvera contraceptives must use conjunction barrier method ] , intrauterine device [ IUD ] ) . The patient must willing able comply study restriction attend regularly schedule clinic visit specify protocol . Patients exclude participate study 1 follow criterion meet : Have clinically significant , uncontrolled medical condition ( treat untreated ) . Have probable diagnosis current sleep disorder primary diagnosis narcolepsy , OSAHS , chronic SWSD . Consume caffeine include coffee , tea and/or caffeinecontaining beverage food average 600 mg caffeine . Use prescription drug disallow protocol clinically significant use overthecounter ( OTC ) drug within 7 day visit 1 . Have history alcohol , narcotic , drug abuse define Diagnostic Statistical Manual American Psychiatric Association , 4th Edition ( DSMIV ) ( American Psychiatric Association 1994 ) . Have positive urine drug screen ( UDS ) ( subject enrol openlabel study within 7 day complete doubleblind study may enrol without UDS result ) . Have clinically significant deviation normal physical examination . Are pregnant lactate . Any woman become pregnant study withdrawn study . Have disorder may interfere drug absorption , distribution , metabolism , excretion ( include gastrointestinal surgery ) . Have know clinically significant drug sensitivity stimulant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>